key: cord-0975020-8p0j9nvq
authors: Zhang, Qian; Bastard, Paul; Liu, Zhiyong; Le Pen, Jérémie; Moncada-Velez, Marcela; Chen, Jie; Ogishi, Masato; Sabli, Ira K. D.; Hodeib, Stephanie; Korol, Cecilia; Rosain, Jérémie; Bilguvar, Kaya; Ye, Junqiang; Bolze, Alexandre; Bigio, Benedetta; Yang, Rui; Arias, Andrés Augusto; Zhou, Qinhua; Zhang, Yu; Onodi, Fanny; Korniotis, Sarantis; Karpf, Léa; Philippot, Quentin; Chbihi, Marwa; Bonnet-Madin, Lucie; Dorgham, Karim; Smith, Nikaïa; Schneider, William M.; Razooky, Brandon S.; Hoffmann, Hans-Heinrich; Michailidis, Eleftherios; Moens, Leen; Han, Ji Eun; Lorenzo, Lazaro; Bizien, Lucy; Meade, Philip; Neehus, Anna-Lena; Ugurbil, Aileen Camille; Corneau, Aurélien; Kerner, Gaspard; Zhang, Peng; Rapaport, Franck; Seeleuthner, Yoann; Manry, Jeremy; Masson, Cecile; Schmitt, Yohann; Schlüter, Agatha; Le Voyer, Tom; Khan, Taushif; Li, Juan; Fellay, Jacques; Roussel, Lucie; Shahrooei, Mohammad; Alosaimi, Mohammed F.; Mansouri, Davood; Al-Saud, Haya; Al-Mulla, Fahd; Almourfi, Feras; Al-Muhsen, Saleh Zaid; Alsohime, Fahad; Al Turki, Saeed; Hasanato, Rana; van de Beek, Diederik; Biondi, Andrea; Bettini, Laura Rachele; D’Angio’, Mariella; Bonfanti, Paolo; Imberti, Luisa; Sottini, Alessandra; Paghera, Simone; Quiros-Roldan, Eugenia; Rossi, Camillo; Oler, Andrew J.; Tompkins, Miranda F.; Alba, Camille; Vandernoot, Isabelle; Goffard, Jean-Christophe; Smits, Guillaume; Migeotte, Isabelle; Haerynck, Filomeen; Soler-Palacin, Pere; Martin-Nalda, Andrea; Colobran, Roger; Morange, Pierre-Emmanuel; Keles, Sevgi; Çölkesen, Fatma; Ozcelik, Tayfun; Yasar, Kadriye Kart; Senoglu, Sevtap; Karabela, Şemsi Nur; Rodríguez-Gallego, Carlos; Novelli, Giuseppe; Hraiech, Sami; Tandjaoui-Lambiotte, Yacine; Duval, Xavier; Laouénan, Cédric; Snow, Andrew L.; Dalgard, Clifton L.; Milner, Joshua D.; Vinh, Donald C.; Mogensen, Trine H.; Marr, Nico; Spaan, András N.; Boisson, Bertrand; Boisson-Dupuis, Stéphanie; Bustamante, Jacinta; Puel, Anne; Ciancanelli, Michael J.; Meyts, Isabelle; Maniatis, Tom; Soumelis, Vassili; Amara, Ali; Nussenzweig, Michel; García-Sastre, Adolfo; Krammer, Florian; Pujol, Aurora; Duffy, Darragh; Lifton, Richard P.; Zhang, Shen-Ying; Gorochov, Guy; Béziat, Vivien; Jouanguy, Emmanuelle; Sancho-Shimizu, Vanessa; Rice, Charles M.; Abel, Laurent; Notarangelo, Luigi D.; Cobat, Aurélie; Su, Helen C.; Casanova, Jean-Laurent
title: Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
date: 2020-10-23
journal: Science
DOI: 10.1126/science.abd4570
sha: ff4dd24dfd0ef5e09b9682f7fafcf1f42a69848c
doc_id: 975020
cord_uid: 8p0j9nvq

Clinical outcome upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from silent infection to lethal coronavirus disease 2019 (COVID-19). We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)– and interferon regulatory factor 7 (IRF7)–dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-threatening COVID-19 pneumonia relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally defined LOF variants underlying autosomal-recessive or autosomal-dominant deficiencies in 23 patients (3.5%) 17 to 77 years of age. We show that human fibroblasts with mutations affecting this circuit are vulnerable to SARS-CoV-2. Inborn errors of TLR3- and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection.

the general hypothesis that life-threatening COVID-19 in some or most patients may be caused by monogenic inborn errors of immunity to SARS-CoV-2 with incomplete or complete penetrance. We sequenced the exome or genome of 659 patients of various ancestries with life-threatening COVID-19 pneumonia and 534 subjects with asymptomatic or benign infection. We tested the specific hypothesis that inborn errors of Toll-like receptor 3 (TLR3)and interferon regulatory factor 7 (IRF7)dependent type I interferon (IFN) immunity that underlie life-threatening influenza pneumonia also underlie life-threatening COVID-19 pneumonia. We considered three loci identified as mutated in patients with life-threatening influenza: TLR3, IRF7, and IRF9. We also con-sidered 10 loci mutated in patients with other viral illnesses but directly connected to the three core genes conferring influenza susceptibility :  TICAM1/TRIF, UNC93B1, TRAF3, TBK1, IRF3,  and NEMO/IKBKG from the TLR3-dependent  type I IFN induction pathway, and IFNAR1,  IFNAR2 , STAT1, and STAT2 from the IRF7and IRF9-dependent type I IFN amplification pathway. Finally, we considered various modes of inheritance at these 13 loci.

We found an enrichment in variants predicted to be loss-of-function (pLOF), with a minor allele frequency <0.001, at the 13 candidate loci in the 659 patients with lifethreatening COVID-19 pneumonia relative to the 534 subjects with asymptomatic or benign infection (P = 0.01). Experimental tests for all 118 rare nonsynonymous variants (including both pLOF and other variants) of these 13 genes found in patients with critical disease identified 23 patients (3.5%), aged 17 to 77 years, carrying 24 deleterious variants of eight genes. These variants underlie autosomal-recessive (AR) deficiencies (IRF7 and IFNAR1) and autosomaldominant (AD) deficiencies (TLR3, UNC93B1, TICAM1, TBK1, IRF3, IRF7, IFNAR1, and IFNAR2) in four and 19 patients, respectively. These patients had never been hospitalized for other life-threatening viral illness. Plasmacytoid dendritic cells from IRF7-deficient patients produced no type I IFN on infection with SARS-CoV-2, and TLR3 −/− , TLR3 +/− , IRF7 −/− , and IFNAR1 −/− fibroblasts were susceptible to SARS-CoV-2 infection in vitro.

CONCLUSION: At least 3.5% of patients with lifethreatening COVID-19 pneumonia had known (AR IRF7 and IFNAR1 deficiencies or AD TLR3, TICAM1, TBK1, and IRF3 deficiencies) or new (AD UNC93B1, IRF7, IFNAR1, and IFNAR2 deficiencies) genetic defects at eight of the 13 candidate loci involved in the TLR3-and IRF7-dependent induction and amplification of type I IFNs. This discovery reveals essential roles for both the double-stranded RNA sensor TLR3 and type I IFN cell-intrinsic immunity in the control of SARS-CoV-2 infection. Type I IFN administration may be of therapeutic benefit in selected patients, at least early in the course Inborn errors of TLR3-and IRF7-dependent type I IFN production and amplification underlie lifethreatening COVID-19 pneumonia. Molecules in red are encoded by core genes, deleterious variants of which underlie critical influenza pneumonia with incomplete penetrance, and deleterious variants of genes encoding biochemically related molecules in blue underlie other viral illnesses. Molecules represented in bold are encoded by genes with variants that also underlie critical COVID-19 pneumonia.

S evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already claimed at least 1 million lives, has been detected in at least 20 million people, and has probably infected at least another 200 million. The clinical manifestations range from silent infection to lethal disease, with an infection fatality rate of 0.1 to 0.9%. Three epidemiological factors increase the risk of severity: (i) increasing age, decade by decade, after the age of 50, (ii) being male, and (iii) having various underlying medical conditions (1). However, even taking these factors into account, there is immense interindividual clinical variability in each demographic category considered. Following on from our human genetic studies of other severe infectious diseases (2, 3), we established the COVID Human Genetic Effort (https:// www.covidhge.com) to test the general hypothesis that in some patients, life-threatening coronavirus disease 2019 (COVID-19) may be caused by monogenic inborn errors of immunity to SARS-CoV-2 with incomplete or complete penetrance (4) . We enrolled 659 patients (74.5% men and 25.5% women, 13.9% of whom died) of various ancestries between 1 month and 99 years of age (Fig. 1A) . These patients were hospitalized for life-threatening pneumonia caused by SARS-CoV-2 (critical COVID-19). We sequenced their whole genome (N = 364) or exome (N = 295), and principal component analysis (PCA) on these data confirmed their ancestries (Fig. 1B) .

We first tested the specific hypothesis that inborn errors of Toll-like receptor 3 (TLR3)-and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity, which underlie life-threatening influenza pneumonia, may also underlie life-threatening COVID-19 pneumonia (5) (Fig. 2) . We considered three loci previously shown to be mutated in patients with critical influenza pneumonia: TLR3 (6), IRF7 (7), and IRF9 (8). We also considered 10 loci mutated in patients with other viral illnesses but directly connected to the three core genes conferring influenza susceptibility: TICAM1/TRIF (9), UNC93B1 (10), TRAF3 (11), TBK1 (12), IRF3 (13), and NEMO/IKBKG (14) in the TLR3-dependent type I IFN induction pathway, and IFNAR1 (15), IFNAR2 (16), STAT1 (17), and STAT2 (18) in the IRF7-and IRF9dependent type I IFN amplification pathway. We collected both monoallelic and biallelic nonsynonymous variants with a minor allele frequency (MAF) <0.001 at all 13 loci. Twelve of the 13 candidate loci are autosomal, whereas NEMO is X-linked. For the latter gene, we considered only a recessive model (19) . Autosomaldominant (AD) inheritance has not been proven for six of the 12 autosomal loci (UNC93B1, IRF7, IFNAR1, IFNAR2, STAT2, and IRF9). Nevertheless, we considered heterozygous variants because none of the patients enrolled had been hospitalized for critical viral infections before COVID-19, raising the possibility that any underlying genetic defects that they might have display a lower penetrance for influenza and other viral illnesses than for COVID-19, which is triggered by a more virulent virus.

We found four unrelated patients with biallelic variants of IRF7 or IFNAR1 (Table 1 and  table S1 ). We also found 113 patients carrying 113 monoallelic variants at 12 loci: TLR3 (N = 7 patients/7 variants), UNC93B1 (N = 10/9), TICAM1 (N = 17/15), TRAF3 (N = 6/6), TBK1 (N = 12/11), IRF3 (N = 5/5), IRF7 (N = 20/13), IFNAR1 (N = 14/13), IFNAR2 (N = 17/15), STAT1 (N = 4/4), STAT2 (N = 11/11), and IRF9 (N = 4/4). We detected no copy number variation for these 13 genes. Unexpectedly, one of these variants has been reported in patients with life-threatening influenza pneumonia (TLR3 p.Pro554Ser) (6, 20) and another was shown to be both deleterious and dominant-negative (IFNAR1 p.Pro335del) (21) . Nine of the 118 biallelic or monoallelic variants were predicted to be LOF (pLOF), whereas the remaining 109 were missense or in-frame indels ( Experimentally deleterious alleles at the influenza susceptibility loci in 3.5% of patients

We tested these 118 variants experimentally in ad hoc overexpression systems. We found that 24 variants of eight genes were deleterious (including all the pLOF variants) because they were loss-of-expression, LOF, or severely hypomorphic: Fig. 2 . Illustration of TLR3-and IRF7-dependent type I IFN production and amplification circuit. Molecules in red are encoded by core genes, deleterious variants of which underlie critical influenza pneumonia with incomplete penetrance; deleterious variants of genes encoding biochemically related molecules in blue underlie other viral illnesses. Type I IFNs also induce themselves. ISGs, interferon-stimulated genes. Fig. 3 . Impact of TLR3, TICAM1, TBK1, IRF3, IRF7, IFNAR1, and IFNAR2 variants on type I IFN signaling. (A) TLR3-deficient P2.1 fibrosarcoma cells were stably transfected with plasmids expressing WT or mutant forms of TLR3, and IFNL1 mRNA levels were determined by reverse transcription quantitative PCR. IFNL1 mRNA levels were expressed relative to the housekeeping gene GUS and then normalized. IFNL1 was undetectable in unstimulated cells. The differences between variants and WT were tested using one-way ANOVA (*P < 0.05). (B) TICAM1deficient SV40-Fib cells were transiently transfected with WT or mutant forms of TICAM1, together with an IFN-b luciferase reporter and a constitutively expressed reporter. Normalized luciferase induction was measured 24 hours after transfection. The differences between variants and WT were tested using one-way ANOVA (*P < 0.05). (C) HEK293T cells were transiently transfected with WT and mutant forms of TBK1, together with an IFN-b luciferase reporter and a constitutively expressed reporter. Normalized luciferase activity was measured 24 hours after transfection. The differences between variants and WT were tested using one-way ANOVA (*P < 0.05). (D) IRF3-deficient HEK293T cells were transiently transfected with WT and mutant forms of IRF3, together with an IFN-b luciferase reporter and a constitutively expressed reporter. Cells were either left untreated or infected with Sendai virus for 24 hours before the normalized measurement of luciferase activity. The differences between variants and WT were evaluated using two-way ANOVA (*P < 0.05). (E) HEK293T cells were transiently transfected with WT and mutant forms of IRF7, together with an IFN-b luciferase reporter and a constitutively expressed reporter. Cells were either left untreated or infected with Sendai virus for 24 hours before the normalized measurement of luciferase activity. The differences between variants and WT were tested using two-way ANOVA (*P < 0.05 for IRF7; homozygosity for IFNAR1) and 19 AD deficiencies. These 23 patients did not carry candidate variants at the other 417 loci known to underlie inborn errors of immunity (table S2) (24) (25) (26) . These findings suggest that at least 23 (3.5%) unrelated patients of the 659 patients tested suffered from a deficiency at one of eight loci among the 13 tested: four patients with a known AR disorder (IRF7 or IFNAR1) (7, 15), 11 with a known AD disorder (TLR3, TICAM1, TBK1, or IRF3) (6, 9, 12, 13, 20) , and eight with a previously unknown AD genetic disorder (UNC93B1, IRF7, IFNAR1, or IFNAR2).

We tested cells from patients with selected genotypes and showed that PHA-driven T cell blasts (PHA-T cells) from patients with AR or AD IRF7 deficiency had low levels of IRF7 expression (Fig. 4A) . We then isolated circulating plasmacytoid dendritic cells (pDCs) from a patient with AR IRF7 deficiency ( fig. S9A ) (7) . These cells were present in normal proportions ( fig. S9B ), but they did not produce any detectable type I or III IFNs in response to SARS-CoV-2, as analyzed by cytometric bead array (CBA), enzyme-linked immunosorbent assay (ELISA), and RNA sequencing (RNAseq) (Fig. 4, B and C) . We also showed that PHA-T cells from a patient with AR IFN-a/b receptor 1 (IFNAR1) deficiency had impaired IFNAR1 expression and responses to IFN-a2 or IFN-b, and that the patient's SV40-transformed fibroblast (SV40-Fib) cells did not respond to IFN-a2 or IFN-b (Fig. 5) . We then infected TLR3 IFNAR1, all of which were previously transduced with angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2). SARS-CoV-2 infection levels were higher in mutant cells than in cells from healthy donors, and transduction of WT IRF7 or IFNAR1 rescued their defects (Fig. 6) . Collectively, these findings showed that AR IRF7 deficiency impaired the production of type I IFN by pDCs stimulated with SARS-CoV-2, whereas AR and AD deficiencies of TLR3 or AR deficiency of IFNAR1 impaired fibroblast-intrinsic type I IFN immunity to SARS-CoV2. They also suggest that heterozygosity for LOF variations at the other five mutated loci also underlie lifethreatening COVID-19.

We tested whether these genotypes impaired the production of type I IFN in vivo during the course of SARS-CoV-2 infection. We measured the levels of the 13 types of IFN-a in the blood of patients during the acute phase of COVID-19. We found that 10 of the 23 patients with mutations for whom samples were available (one with AR IRF7 deficiency, four with AD IRF7 deficiency, one with AD TLR3 deficiency, two with AD TBK1 deficiency, one with AR IFNAR1 deficiency, and one with AD TICAM1 deficiency) had serum IFN-a levels <1 pg/ml ( Fig. 7) . By contrast, previously published cohorts of patients hospitalized with unexplained, severe COVID-19 had various serum IFN-a levels, significantly higher than our 10 patients [one-way analysis of variance (ANOVA), P = 1.4 × 10 −7 ; Fig. 7 ] (27, 28) . Another 29 patients from our cohort displaying auto-antibodies (auto-Abs) against type I IFNs, reported in an accompanying paper, had undetectable levels of serum IFN-a (29) . Moreover, none of the 23 patients with LOF mutations of the eight genes had detectable auto-Abs against type I IFNs (29), strongly suggesting that the two mechanisms of disease are similar but independent. Excluding patients with auto-Abs against type I IFN from the burden test of pLOF variants at the 12 autosomal loci strengthened the association signal (P = 0.007; OR = 8.97; 95% CI = 1.13 to 71.09).

Inborn errors of TLR3-and IRF7-dependent type I immunity underlie critical COVID-19

Collectively, our data suggest that at least 23 of the 659 patients with life-threatening COVID-19 pneumonia studied had known (six disorders) or new (four disorders) genetic defects at eight loci involved in the TLR3-and IRF7-dependent induction and amplification of type I IFNs. This discovery reveals the essential role of both the double-stranded RNA sensor TLR3 and type I IFN cell-intrinsic immunity in the control of SARS-CoV-2 infection in the lungs, consistent with their previously documented roles in pulmonary immunity to influenza virus (5) (6) (7) (8) . These genotypes were silent until infection with SARS-CoV-2. The most thoughtprovoking examples are the AR deficiencies of IRF7 and IFNAR1. AR IRF7 deficiency was diagnosed in two individuals aged 49 and 50 years, and AR IFNAR1 deficiency was diagnosed in two individuals aged 26 and 38 years, and none of the four patients had a prior history of life-threatening infections (Table 1) . One patient with IRF7 deficiency was tested and was seropositive for several common viruses, including various influenza A and B viruses (figs. S10 and S11). These genetic defects therefore display incomplete penetrance for influenza respiratory distress and only manifested clinically upon infection with the more virulent SARS-CoV-2.

The AR form of IFNAR1 deficiency highlights the importance of type I IFN production relative to type III IFN production, which is also impaired by defects of TLR3, IRF7, and IRF9 (5). This conclusion is also supported by our accompanying report of neutralizing auto-Abs against type I IFNs, but not type III IFNs, in other patients with life-threatening COVID-19 pneumonia (29) . Inborn errors of TLR3-and IRF7-dependent type I IFN immunity at eight loci were found in as many as 23 patients (3.5%) of various ages (17 to 77 years) and ancestries (various nationalities from Asia, Europe, Latin America, and the Middle East) and in patients of both sexes (Table 1 ). Our findings suggest that there may be mutations in other type I IFN-related genes in other patients with lifethreatening COVID-19 pneumonia. They also suggest that the administration of type I IFN may be of therapeutic benefit in selected patients, at least early in the course of SARS-CoV-2 infection.

We included in this study 659 patients with life-threatening COVID-19 pneumonia, defined as patients with pneumonia who developed critical disease, whether pulmonary with mechanical ventilation (CPAP, BIPAP, intubation, hi-flow oxygen), septic shock, or with any other organ damage requiring admission to the intensive care unit. Patients who developed Kawasaki-like syndrome were excluded. The age of the patients ranged from 0.1 to 99 years, with a mean age of 51.8 years (SD 15.9 years), and 25.5% of the patients were female. As controls, we enrolled 534 individuals infected with SARS-CoV-2 based on a positive polymerase chain reaction (PCR) and/or serological test and/or the presence of typical symptoms such as anosmia or ageusia after exposure to a confirmed COVID-19 case, who remained asymptomatic or developed mild, self-healing, ambulatory disease.

Genomic DNA was extracted from whole blood. For the 1193 patients and controls included, the whole exome (N = 687) or whole genome (N = 506) was sequenced. We used the Genome Analysis Software Kit (GATK) (version 3.4-46 or 4) best-practice pipeline to analyze our whole-exome-sequencing data (30) . We aligned the reads obtained with the human reference genome (hg19) using the maximum exact matches algorithm in Burrows-Wheeler Aligner software (31) . PCR duplicates were removed with Picard tools (http://broadinstitute. github.io/picard/). The GATK base quality score recalibrator was applied to correct sequencing artifacts.

All of the variants were manually curated using Integrative Genomics Viewer (IGV) and confirmed to affect the main functional protein isoform by checking the protein sequence before inclusion in further analyzes. The main functional protein isoforms were TLR3 (NM_ (NM_005419.4), and IRF9 (NM_006084.5). The analysis of IKBKG was customized to unmask the duplicated region in IKBKG using a specific pipeline previously described (32) . We searched the next-generation-sequencing data for deletions in the 13 genes of interest using both the HMZDelFinder (33) and CANOES (34) algorithms.

We performed an enrichment analysis on our cohort of 659 patients with life-threatening COVID-19 pneumonia and 534 SARS-CoV2infected controls, focusing on 12 autosomal IFN-related genes. We considered variants that were pLOF with a MAF <0.001 (gnomAD version 2.1.1) after experimentally demonstrating that all of the pLOF variants seen in the cases were actually LOF. We compared the proportion of individuals carrying at least one pLOF variant of the 12 autosomal genes in cases and controls by means of logistic regression with the likelihood ratio test. We ac-counted for the ethnic heterogeneity of the cohorts by including the first three principal components of the PCA in the logistic regression model. PC adjustment is a common and efficient strategy for accounting for different ancestries of patients and controls in the study of rare variants (35) (36) (37) (38) . We checked that our adjusted burden test was well calibrated by also performing an analysis of enrichment in rare (MAF <0.001) synonymous variants of the 12 genes. PCA was performed with Plink version 1.9 software on whole-exome-and wholegenome-sequencing data and the 1000 Genomes (1kG) Project phase 3 public database as a reference, using 27,480 exonic variants with a MAF >0.01 and a call rate >0.99. The OR was also estimated by logistic regression and adjusted for ethnic heterogeneity.

Cell lines or SV40-Fib cells with known defects were transiently or stably transfected with WT, mutant variants, IFN-b-or ISRE-firefly luciferase reporter, and pRL-TK-Renilla luciferase reporter. Reporter activity was measured with the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Firefly luciferase activity was normalized against Renilla luciferase activity and expressed as a fold change. TRAF3-deficient human embryonic kidney (HEK) 293T cells were kindly provided by M. Romanelli (39) .

pDC activation by SARS-CoV-2 and cytokine production pDCs from an IRF7 −/− patient and a healthy donor matched for age and sex were cultured in the presence of medium alone, influenza virus (A/PR/8/34, 2 mg/ml; Charles River Laboratories), or the SARS-CoV-2 primary strain 220_95 (GISAID accession ID: EPI_ISL_469284) at a multiplicity of infection (MOI) of 2. After 12 hours of culture, pDC supernatant was collected for cytokine quantification. IFN-a2 levels were measured using CBA analyzis (BD Biosciences) in accordance with the manufacturer's protocol using a 20 pg/ml detection limit. IFN-l1 secretion was measured in an ELISA (R&D Systems, DuoSet DY7246), in accordance with the manufacturer's instructions.

To make patient-derived fibroblasts permissive to SARS-CoV-2 infection, we delivered human ACE2 and TMPRSS2 cDNA to cells by lentivirus transduction using a modified SCRPSY vector (GenBank ID: KT368137.1). SARS-CoV-2 strain USA-WA1/2020 was obtained from BEI Resources. ACE2/TMPRSS2-transduced cells were either left untreated or treated with 500 U/ml IFN-b (11415-1, PBL Assay Science) 4 hours before infection. Cells were infected with SARS-CoV-2 (MOI = 0.5) for 1 hour at 37°C. After 24 hours of infection, cells were fixed and taken out of the BSL3 for staining. After fixation, cells were stained with SARS-CoV-2 and ACE2 primary antibodies (0.5 and 1 mg/ml, respectively). Primary antibodies were as follows: for SARS-CoV-2, human monoclonal anti-spike-SARS-CoV-2 C121 antibody (40) , and for ACE2, mouse monoclonal Alexa Fluor 488conjugated antibody (FAB9332G-100UG, R&D Systems). Images were acquired with an ImageXpress Micro XLS microscope (Molecular Devices) using the 4× objective. MetaXpress software (Molecular Devices) was used to obtain singlecell mean fluorescence intensity (MFI) values.

Data analysis on single-cell MFI values was done in the R environment (version 4.0.2). ACE2/TMPRSS2-transduced cells were classified as ACE2 positive when the ACE2 log MFI was superior to the log mean MFI of mocktransduced cells plus 2.5 SDs. We excluded all wells with <150 ACE2-positive cells before SARS-CoV-2 scoring. ACE2-expressing cells were classified SARS-CoV-2 positive when the fluorescence intensity value was superior to Zhang (29) . P values indicated were evaluated using one-way ANOVA. 

Serum IFN-a concentrations were determined using Simoa technology, with reagents and procedures obtained from Quanterix Corporation (Quanterix SimoaTM IFNa Reagent Kit, Lexington, MA, USA). According to the manufacturer's instructions, the working dilutions were 1:2 for all sera in working volumes of 170 ml. 

Emerging pandemic diseases: How we got to COVID-19

Lethal Infectious Diseases as Inborn Errors of Immunity: Toward a Synthesis of the Germ and Genetic Theories

The human genetic determinism of lifethreatening infectious diseases: Genetic heterogeneity and physiological homogeneity?

COVID Human Genetic Effort, A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection

Human genetics of life-threatening influenza pneumonitis

Severe influenza pneumonitis in children with inherited TLR3 deficiency

Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency

Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency

Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency

Herpes simplex virus encephalitis in human UNC-93B deficiency

Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis

Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood

Functional IRF3 deficiency in a patient with herpes simplex encephalitis

NEMO is a key component of NF-kB-and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus

Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines

Human IFNAR2 deficiency: Lessons for antiviral immunity

Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency

STAT2 deficiency and susceptibility to viral illness in humans

X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling

TLR3 deficiency in patients with herpes simplex encephalitis

A proline deletion in IFNAR1 impairs IFNsignaling and underlies increased resistance to tuberculosis in humans

Identification of an IRF3 variant and defective antiviral interferon responses in a patient with severe influenza

Defective interferon priming and impaired antiviral responses in a patient with an IRF7 variant and severe influenza

Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee

Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification

Human inborn errors of immunity: An expanding universe

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Type I IFN immunoprofiling in COVID-19 patients

Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

A framework for variation discovery and genotyping using next-generation DNA sequencing data

Fast and accurate short read alignment with Burrows-Wheeler transform

Rescue of recurrent deep intronic mutation underlying cell type-dependent quantitative NEMO deficiency

Homozygous and hemizygous CNV detection from exome sequencing data in a Mendelian disease cohort

CANOES: Detecting rare copy number variants from whole exome sequencing data

Controlling for human population stratification in rare variant association studies

The impact of a fine-scale population stratification on rare variant association test results

Adjusting for population stratification in a fine scale with principal components and sequencing data

Tuberculosis and impaired IL-23-dependent IFN-g immunity in humans homozygous for a common TYK2 missense variant

TRAF3 Is Required for NF-kB Pathway Activation Mediated by HTLV Tax Proteins

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Imagine COVID Group, French COVID Cohort Study Group, CoV-Contact Cohort, Amsterdam UMC Covid-19 Biobank

Regione Lombardia, Italy (project "Risposta immune in pazienti con COVID-19 e comorbidità"), and the Intramural Research Program of the NIAID, NIH. The laboratory of Genomes & Cell Biology of Disease is supported by

are supported by FWO G0C8517N -GOB5120N. The VS team was supported by

is supported by a UKRI Future Leaders Fellowship (MR/S032304/1). S.Z.A.-M. is supported by the Elite Journals Program at King Saud University through grant no. PEJP-16-107. The J.M. laboratory is supported by Columbia University COVID biobank and grant no. UL1TR001873

Work at the Neurometabolic Diseases Laboratory received funding from the European Union's Horizon 2020 research and innovation program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342) to A

Spanish Ministry of Science and Innovation, with the funding of European Regional Development Fund-European Social Fund -FEDER-FSE

Work on COVID-19 at the A.G.-S. laboratory is partly supported by NIH supplements to grants U19AI135972, U19AI142733, and R35 HL135834, and to contract HHSN272201800048C, by a DoD supplement to grant W81XWH-20-1-0270, by DARPA project HR0011-19-2-0020, by CRIP (Center for Research on Influenza Pathogenesis), a NIAID funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract HHSN272201400008C), by an NIAID funded Collaborative Influenza Vaccine Innovation Center (SEM-CIVIC, contract 75N93019C00051) and by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611(5384)) and anonymous donors. The Virscan analysis presented in fig. S11 was performed with financial support from Sidra Medicine

Semra Calimli 39 , Ruggero Capra 40 , Maria Carrabba 41 , Carlos Casasnovas 42 , Marion Caseris 43 , Martin Castelle 44 , Francesco Castelli 45 , Martín Castillo de Vera 46

25 Service de Médecine Intensive-Réanimation et Pneumologie

Pediatric Infectious Diseases Unit

36 Department of Children's Diseases and Pediatric Surgery, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine. 37 Human Genome and Stem-Cell Research Center

46 Doctoral Health Care Center, Canarian Health System

53 Division of Clinical Immunology and Allergy, Department of Internal Medicine

57 Fundació Docència i Recerca Mútua Terrassa

62 Specialized Immunology Laboratory of Dr. Shahrooei

74 Centre Hospitalier Fleyriat

Instituto Tecnológico y de Energías Renovables (ITER)

86 Hospital General Universitario and Instituto de Investigación Sanitaria "Gregorio Marañón

93 Division of Allergy and Immunology

95 Department of Internal Medicine

Jolimont Hospital; Department of Pediatric Hemato-Oncology, HUDERF, Brussels, Belgium. 102 Intensive Care Unit, Marqués de Valdecilla Hospital

121 Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Warsaw, Poland. 122 Oncobiologie Génétique Bioinformatique

Adult Immunodeficiency Unit, Majakka, Helsinki, Finland. 192 Fundació Docència i Recerca Mútua Terrassa, Terrassa, Spain. 193 Department of Pulmonology

202 Department of Internal Diseases and Pediatrics, Primary Immune Deficiency Research Lab, Centre for Primary Immunodeficiency Ghent, Jeffrey Modell Diagnosis and Research Centre

208 Hematology Department

215 Department of Chest Diseases

218 General Intensive Care Unit

INSERM UMR 1163

Céline Dorival 8 , François Dubos 19 , Xavier Duval 4 , Philippine Eloy 4 , Vincent VE Enouf 20

Drugs for Neglected Diseases Initiative

UMR 3569 CNRS

3 Institut Pasteur, UMR 3569 CNRS

IAME, Inserm UMR 1137, F-75018

INSERM U1111, CNRS UMR 5308

17 Service des Explorations Fonctionnelles, Hôpital Bichat-Claude Bernard

Rutger Koning 4 , Niels van Mourik 2 , Jeaninne Nellen 1 , Frederique Paulus 2 , Edgar Peters 1 , Tom van der Poll 1

Amsterdam, Netherlands. 13 Department of Internal Medicine

Group of Primary Immunodeficiencies, Antioquia, Colombia. 7 The Genetics Institute

Pediatric Infectious Disease Departement, Faculty of Medicine and Pharmacy, Averroes University Hospital; LICIA Laboratoire d'Immunologie Clinique, d'Inflammation et d'Allergie

16 Emory University Department of Pediatrics and Children's Healthcare of Atlanta

23 Bai Jerbai Wadia Hospital for Children, Mumbai, India. 24 School of Medicine and Public Health

30 Department of Paediatric Immunology and Pulmonology

37 Hellenic Pasteur Institute

51 Singapore Immunology Network, Singapore. 52 National Institute of Allergy and Infectious Diseases

60 Faculdades Pequeno Príncipe e Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil. 61 Neurometabolic Diseases Laboratory, IDIBELL-Hospital Duran I Reynals

63 Infectious Diseases Horizontal Technology Center and Singapore Immunology Network, Agency for Science Technology (A*STAR), Singapore. 64 Medical Genetics

69 Uniformed Services University of the Health Sciences

74 Holy Family Red Crescent Medical College; Centre for Precision Therapeutics, NeuroGen Children's Healthcare; Genetics and Genomic Medicine Centre, NeuroGen Children's Healthcare

The Hospital for Sick Children

Chauvin 2,4 , Kazuyuki Meguro 1,2 , Elana Shaw 1,2 , Michael Lenardo 2,4 , Justin Lack 5 , Eric Karlins 6 , Daniel M

Infectious Disease Susceptibility Program, Research Institute, McGill University Health Centre, Montréal, Québec, Canada. 27 Specialized Immunology Laboratory of Dr. Shahrooei, Sina Medical Complex, Ahvaz, Iran. 28 Department of Microbiology and Immunology, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium. 29 Department of Pathology and Laboratory Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia. 30 Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 31 The Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of, Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti, University of Medical Sciences, Tehran, Iran. 32 Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti, Iran. 33 National Center of Genomics Technology, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia. 34 Dasman Diabetes Institute, Department of Genetics and Bioinformatics, Kuwait. 35 

science.sciencemag.org/content/370/6515/eabd4570/suppl/DC1 Materials and Methods Figs. S1 to S11 Tables S1 and S2 References (42 and 43) MDAR Reproducibility Checklist View/request a protocol for this paper from Bio-protocol.